Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases
“Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases”, vol. 15, p. -, 2016.
, Cardiovascular and cerebrovascular diseases (CCVDs) are common and have high rates of morbidity, mortality, and recurrence. Thrombin-activatable fibrinolysis inhibitor (TAFI) is also known as carboxypeptidase B2 and is encoded by the CPB2 gene; CPB2 polymorphisms have been explored in a variety of studies, but their correlation to the risk of CCVDs remains ambiguous. We examined the hypothesized associations between CPB2 mutations and CCVDs in a general population.